Ask AI

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

Gain in-depth knowledge on the medical need and rationale for using PARP inhibitor–based treatment in patients with metastatic castration-resistant prostate cancer, including best practices in testing to inform treatment selection, recent guideline updates, and toxicity management, through an on-demand webcast with accompanying slides and an expert-written ClinicalThought.

Share

Program Content

Events

  • Live Event Complementing PARP Inhibition in Metastatic CRPC
    Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

Single Agent PARPis in mCRPC
Complementing PARP Inhibition in Metastatic CRPC: PARP Inhibitors as Single Agents
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

PARP Inhibitor Combo Tx in mCRPC
Complementing PARP Inhibition in Metastatic CRPC: Optimal Use of PARP Inhibitor Combination Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

Genomic Testing and PARPi AEs in mCRPC
Complementing PARP Inhibition in Metastatic CRPC: Genomic Testing and Considerations for Managing AEs
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

Activities

Combining Therapeutic Approaches in Metastatic CRPC
Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 19, 2025

Expires: December 18, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Johnson & Johnson and Pfizer Inc.

Johnson & Johnson

Pfizer, Inc.